================================================================================
CLINICAL ANALYSIS REPORT
================================================================================

Patient: Jane TestPatient
Gender: female
DOB: 1968-03-15
Report Date: 2025-12-29 11:30:11

DIAGNOSES:
  - Stage IV High-Grade Serous Ovarian Carcinoma (HGSOC), Platinum-Resistant

CURRENT MEDICATIONS:
  - Bevacizumab (Avastin) (active)
  - Paclitaxel (completed)
  - Carboplatin (completed)

MOLECULAR ANALYSIS SUMMARY:
--------------------------------------------------------------------------------

1. DIFFERENTIAL EXPRESSION (tumor_core vs stroma):
   Total DEGs: 17
   Upregulated: 13
   Downregulated: 4

   Top 5 upregulated genes in tumor:
      TP53: log2FC = 4.654, FDR = 5.04e-20
      KRT8: log2FC = 4.345, FDR = 2.68e-18
      ABCB1: log2FC = 4.285, FDR = 4.20e-18
      BCL2L1: log2FC = 3.683, FDR = 2.95e-19
      MKI67: log2FC = 3.564, FDR = 1.22e-14

2. SPATIAL ORGANIZATION:
   Spatially variable genes: 31

   Top 5 spatially clustered genes:
      HIF1A: Moran's I = 0.1411, p = 0.00e+00
      BCL2L1: Moran's I = 0.1269, p = 0.00e+00
      CD3D: Moran's I = 0.1103, p = 0.00e+00
      KRT8: Moran's I = 0.1071, p = 0.00e+00
      MYC: Moran's I = 0.1065, p = 0.00e+00

3. TUMOR MICROENVIRONMENT:
   Cell type enrichment by region:

   necrotic_hypoxic:
      fibroblasts: 75.7
      immune_cells: 83.5
      hypoxic: 607.5
      resistant: 73.1
   stroma:
      fibroblasts: 748.6
      immune_cells: 76.3
      hypoxic: 70.2
      resistant: 61.2
   stroma_immune:
      fibroblasts: 362.6
      immune_cells: 603.3
      hypoxic: 95.0
      resistant: 98.6
   tumor_core:
      fibroblasts: 67.1
      immune_cells: 81.7
      hypoxic: 60.6
      resistant: 716.8
   tumor_interface:
      fibroblasts: 65.9
      immune_cells: 60.8
      hypoxic: 64.1
      resistant: 384.0
   tumor_proliferative:
      fibroblasts: 64.1
      immune_cells: 80.5
      hypoxic: 61.1
      resistant: 728.7

CLINICAL IMPLICATIONS:
--------------------------------------------------------------------------------

Drug Resistance Markers Detected:
  - PIK3CA: 3.11× fold change
  - AKT1: 3.24× fold change
  - MTOR: 3.17× fold change
  - ABCB1: 4.29× fold change

  ⚠️  Consider:
     - PI3K/AKT pathway inhibitors (Alpelisib, Capivasertib)
     - MDR reversal agents

Hypoxic Regions Identified:
  - HIF1A: Moran's I = 0.1411 (spatially clustered)
  - VEGFA: Moran's I = 0.1053 (spatially clustered)
  - CA9: Moran's I = 0.1026 (spatially clustered)

  ⚠️  Consider:
     - Hypoxia-targeting agents (Evofosfamide, TH-302)
     - VEGF inhibitors (Bevacizumab)

================================================================================
DISCLAIMER:
This analysis is for RESEARCH PURPOSES ONLY.
NOT validated for clinical decision-making.
All treatment decisions must be made by qualified oncologists.
================================================================================